Nateglinide (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nateglinide" in Italian language version.

refsWebsite

Global rank Italian rank

13nih.gov

4^th place

9^th place

5oadoi.org

799^th place

22^nd place

5doi.org

2^nd place

7^th place

2archive.org

6^th place

8^th place

archive.org

TL. Levien, DE. Baker; RK. Campbell; JR. White, Nateglinide therapy for type 2 diabetes mellitus., in Ann Pharmacother, vol. 35, n. 11, novembre 2001, pp. 1426-34, PMID 11724096.
J. Andrews, Restoring post-prandial insulin release in type 2 diabetes., in Hosp Med, vol. 63, n. 2, febbraio 2002, pp. 95-8, PMID 11902096.

doi.org

dx.doi.org

W. Hanif, S. Kumar, Nateglinide: a new rapid-acting insulinotropic agent., in Expert Opin Pharmacother, vol. 2, n. 6, giugno 2001, pp. 1027-31, DOI:10.1517/14656566.2.6.1027, PMID 11585005.
S. Hu, BR. Boettcher; BE. Dunning, The mechanisms underlying the unique pharmacodynamics of nateglinide., in Diabetologia, 46 Suppl 1, marzo 2003, pp. M37-43, DOI:10.1007/s00125-002-0935-1, PMID 12652357.
IW. Campbell, Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus., in Int J Clin Pract, vol. 59, n. 10, ottobre 2005, pp. 1218-28, DOI:10.1111/j.1368-5031.2005.00669.x, PMID 16178991.
G. Grunberger, Quo vadis nateglinide? Ten-year perspective., in Expert Opin Pharmacother, vol. 12, n. 13, settembre 2011, pp. 2097-106, DOI:10.1517/14656566.2011.600305, PMID 21801074.
LF. Van Gaal, IH. De Leeuw, Rationale and options for combination therapy in the treatment of Type 2 diabetes., in Diabetologia, 46 Suppl 1, marzo 2003, pp. M44-50, DOI:10.1007/s00125-002-0936-0, PMID 12652358.

nih.gov

ncbi.nlm.nih.gov

M. Kikuchi, [Clinical trial of AY4166]., in Nihon Rinsho, 55 Suppl, novembre 1997, pp. 164-70, PMID 9434462.
N. Kondo, [Preclinical studies of AY4166 (A-4166)]., in Nihon Rinsho, 55 Suppl, novembre 1997, pp. 159-63, PMID 9434461.
W. Hanif, S. Kumar, Nateglinide: a new rapid-acting insulinotropic agent., in Expert Opin Pharmacother, vol. 2, n. 6, giugno 2001, pp. 1027-31, DOI:10.1517/14656566.2.6.1027, PMID 11585005.
T. Ikenoue, N. Kondo, [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes]., in Nihon Yakurigaku Zasshi, vol. 116, n. 3, settembre 2000, pp. 171-80, PMID 11031747.
S. Hu, BR. Boettcher; BE. Dunning, The mechanisms underlying the unique pharmacodynamics of nateglinide., in Diabetologia, 46 Suppl 1, marzo 2003, pp. M37-43, DOI:10.1007/s00125-002-0935-1, PMID 12652357.
JF. McLeod, Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent., in Clin Pharmacokinet, vol. 43, n. 2, 2004, pp. 97-120, PMID 14748619.
TL. Levien, DE. Baker; RK. Campbell; JR. White, Nateglinide therapy for type 2 diabetes mellitus., in Ann Pharmacother, vol. 35, n. 11, novembre 2001, pp. 1426-34, PMID 11724096.
IW. Campbell, Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus., in Int J Clin Pract, vol. 59, n. 10, ottobre 2005, pp. 1218-28, DOI:10.1111/j.1368-5031.2005.00669.x, PMID 16178991.
G. Grunberger, Quo vadis nateglinide? Ten-year perspective., in Expert Opin Pharmacother, vol. 12, n. 13, settembre 2011, pp. 2097-106, DOI:10.1517/14656566.2011.600305, PMID 21801074.
CJ. Dunn, D. Faulds, Nateglinide., in Drugs, vol. 60, n. 3, settembre 2000, pp. 607-615; discussion 616-7, PMID 11030470.
MK. Israel, E. Istvan; MA. Baron, Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes., in Vasc Health Risk Manag, vol. 4, n. 6, 2008, pp. 1167-78, PMID 19337530.
J. Andrews, Restoring post-prandial insulin release in type 2 diabetes., in Hosp Med, vol. 63, n. 2, febbraio 2002, pp. 95-8, PMID 11902096.
LF. Van Gaal, IH. De Leeuw, Rationale and options for combination therapy in the treatment of Type 2 diabetes., in Diabetologia, 46 Suppl 1, marzo 2003, pp. M44-50, DOI:10.1007/s00125-002-0936-0, PMID 12652358.

oadoi.org

W. Hanif, S. Kumar, Nateglinide: a new rapid-acting insulinotropic agent., in Expert Opin Pharmacother, vol. 2, n. 6, giugno 2001, pp. 1027-31, DOI:10.1517/14656566.2.6.1027, PMID 11585005.
S. Hu, BR. Boettcher; BE. Dunning, The mechanisms underlying the unique pharmacodynamics of nateglinide., in Diabetologia, 46 Suppl 1, marzo 2003, pp. M37-43, DOI:10.1007/s00125-002-0935-1, PMID 12652357.
IW. Campbell, Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus., in Int J Clin Pract, vol. 59, n. 10, ottobre 2005, pp. 1218-28, DOI:10.1111/j.1368-5031.2005.00669.x, PMID 16178991.
G. Grunberger, Quo vadis nateglinide? Ten-year perspective., in Expert Opin Pharmacother, vol. 12, n. 13, settembre 2011, pp. 2097-106, DOI:10.1517/14656566.2011.600305, PMID 21801074.
LF. Van Gaal, IH. De Leeuw, Rationale and options for combination therapy in the treatment of Type 2 diabetes., in Diabetologia, 46 Suppl 1, marzo 2003, pp. M44-50, DOI:10.1007/s00125-002-0936-0, PMID 12652358.